Ranked #2,361 of 8,699 institutional investors
SR One Capital Management, LP
Redwood City, CA
$996M
US stock portfolio at live prices · today −$6.5M (−0.65%)
Live prices, last trade 9:49 AM ET
- Value at quarter end (Q3 2026)
- $1.15B
- Change from Q2 2026
- +$110.5M (+10.64%)
- Positions
- 15 · 3 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$119M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesMANE 25.5%ADRX 14.1%ZBIO 12.7%AVLN 9.59%ODTX 6.61%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| MANE Veradermics Inc | 2,080,119 | $253M | 25.5% | Reduced −13% |
| ADRX ADARx Pharmaceuticals, Inc. | 9,936,661 | $140M | 14.1% | New |
| ZBIO Zenas BioPharma, Inc. | 5,037,854 | $127M | 12.7% | Unchanged |
| AVLN Avalyn Pharma Inc. | 3,308,649 | $95.5M | 9.59% | Unchanged |
| ODTX Odyssey Therapeutics, Inc. | 3,794,883 | $65.8M | 6.61% | Unchanged |
| DSGN Design Therapeutics, Inc. | 6,526,476 | $61.3M | 6.16% | Unchanged |
| ORIC ORIC Pharmaceuticals, Inc. | 4,615,384 | $36.3M | 3.65% | Unchanged |
| KRSA Korsana Biosciences, Inc. | 613,915 | $23.2M | 2.33% | New |
| MOBI Mobia Medical, Inc. | 1,986,072 | $23.1M | 2.32% | Unchanged |
| MLYS Mineralys Therapeutics, Inc. | 1,563,966 | $22.0M | 2.21% | Unchanged |
| SPRY ARS Pharmaceuticals, Inc. | 4,012,903 | $13.5M | 1.36% | Unchanged |
| ALMS Alumis Inc. | 1,959,896 | $8.4M | 0.84% | Unchanged |
| NKTX Nkarta, Inc. | 3,333,333 | $3.9M | 0.39% | Unchanged |
| RARE Ultragenyx Pharmaceutical Inc. | 137,753 | $2.4M | 0.24% | Unchanged |
| ENGN enGene Therapeutics Inc. | 747,750 | $1.3M | 0.13% | New |